Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

The company will prioritize its cash in funding its ongoing Phase 1/2 PRISM clinical trial and Phase 3 4FRONT program.

Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

Several companies have announced new executives and board members appointments as they prepare for growth in 2025.

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Eyebright Medical's Loong Crystal PR IOL received Class III certification from China's NMPA, indicating high regulatory ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration and Astellas.

ViGeneron GmbH, a clinical-stage gene therapy company based in Munich, Germany, shared details of two new milestones in an ...

These resources include downloadable fact sheets, glaucoma financial assistance resources, shareable social media graphics, ...

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss deep learning systems and whether they can distinguish between optic disc drusen and true papilledema ...

The company also released additional data from its phase 2 clinical trial in addition to the LONGITUDE program design.